Capital One analyst Zegbeh Jallah downgraded Outlook Therapeutics to Equalweight from Overweight with a price target of $1, down from $5, after the company received a CRL for ONS-5010 from the FDA.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on OTLK:
- Outlook Therapeutics downgraded to Neutral from Buy at Guggenheim
- Outlook Therapeutics downgraded to Hold from Buy at Brookline
- Outlook Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald
- Outlook Therapeutics (NASDAQ: OTLK) Craters 83% on FDA Setback
- Outlook Therapeutics downgraded to Neutral from Buy at BTIG